Acelyrin (Acelyrin) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Debt-to-Equity?

Acelyrin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Acelyrin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.13 Mil. Acelyrin's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $644.07 Mil. Acelyrin's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Acelyrin's Debt-to-Equity or its related term are showing as below:

SLRN's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Acelyrin Debt-to-Equity Historical Data

The historical data trend for Acelyrin's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin Debt-to-Equity Chart

Acelyrin Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

Acelyrin Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial					-0.01	-	-	-	-

Competitive Comparison of Acelyrin's Debt-to-Equity

For the Biotechnology subindustry, Acelyrin's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acelyrin's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Acelyrin's Debt-to-Equity falls into.

Acelyrin Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Acelyrin's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.194)	/	656.337
	=	0.00

Acelyrin's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.134)	/	644.067
	=	0.00

Acelyrin (NAS:SLRN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Acelyrin Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Acelyrin's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acelyrin (Acelyrin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301

Website

https://www.acelyrin.com

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.

Executives

Shao-lee Lin	director, officer: Chief Executive Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie	officer: Interim CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg	director, 10 percent owner
Henry O Gosebruch	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier	officer: CFO and CBO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim	officer: Chief Legal & Admin. Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston	officer: Chief People Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso	officer: Chief Medical Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker	director	C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p.	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp	director, 10 percent owner, other: See Remarks	1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper	10 percent owner	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria	officer: Chief Operating Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361